Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Increases By 83.0%

Candel Therapeutics, Inc. (NASDAQ:CADL) was the target of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 1,550,000 shares, a growth of 83.0% from the May 15th total of 846,800 shares. Based on an average daily trading volume, of 5,570,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 8.3% of the company’s stock are short sold.

Candel Therapeutics Stock Down 3.3 %

Shares of CADL traded down $0.25 during midday trading on Friday, hitting $7.29. The company had a trading volume of 321,487 shares, compared to its average volume of 898,361. The company’s 50-day simple moving average is $8.14 and its 200-day simple moving average is $3.82. The company has a debt-to-equity ratio of 1.66, a quick ratio of 2.00 and a current ratio of 2.00. The firm has a market capitalization of $216.95 million, a P/E ratio of -5.70 and a beta of -0.84. Candel Therapeutics has a 1 year low of $0.66 and a 1 year high of $14.30.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.28) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Candel Therapeutics will post -0.91 EPS for the current year.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.